Friedegund Meier

26PUBLICATIONS
145CO-AUTHORS
Molecular targetsPredictive and prognostic markersSolid tumoursMetabolic medicineTumour immunology
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (26)

|Aug 11, 2026
Neoadjuvant Intralesional Daromun (L19IL2/L19TNF) in Resectable Locally Advanced Melanoma: An Update on the Efficacy and Safety Results of the PIVOTAL Phase III Trial.

|Jul 02, 2026
Years of life lost in patients with a false-negative diagnosis of primary melanoma. A prospective study of the German Central Malignant Melanoma Registry involving 9063 patients over 28 years.

|Jun 04, 2026
Intrathecal nivolumab in metastatic solid tumors with leptomeningeal disease: dose escalation part of the multicenter IT-PD1/NOA-26 phase 1 trial.

|Jan 30, 2026
¹H-NMR serum metabolomic profiling from clinical routine identifies signatures of progressive melanoma metastasis.

Frank Friedrich Gellrich, Cosima Hufnagel, Alexander M Funk

|Jan 27, 2026
Autoantibodies as predictors for immune-related adverse events in checkpoint inhibition therapy of metastatic melanoma.

Robin Reschke, Petra Budde, Hans-Dieter Zucht

|Jan 20, 2026
Vδ1 T-cell subset appears to be responsive to PD-1 blockade therapy and is associated with survival in melanoma.

Nicola Herold, Jonas Bochem, Johanna Leyens

Pageof 5

Frequent Collaborators

9 joint publications

Carola Berking

9 joint publications

Dirk Schadendorf

6 joint publications

Jessica Cecile Hassel

6 joint publications

Frank Friedrich Gellrich